^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    B7-H3 inhibitor

    Related drugs:
    3d
    pH/ROS-Responsive Injectable Hydrogel Co-Loaded with B7-H3 Blocker and NETs Suppressor Boosts OSCC Synergistic Immunotherapy. (PubMed, Adv Sci (Weinh))
    This study presents an injectable pH/ROS-dual-responsive hydrogel co-loaded with enoblituzumab (B7-H3 blocker) and Cl-amidine (NETs suppressor)...The hydrogel exhibits excellent biocompatibility without systemic toxicity. This TME-responsive combination strategy offers a promising approach to enhance immunotherapy efficacy and overcome immune resistance in OSCC.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • CD4 (CD4 Molecule)
    |
    enoblituzumab (MGA271)
    11d
    131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (clinicaltrials.gov)
    P2, N=62, Active, not recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Oct 2030 --> Sep 2027 | Trial primary completion date: Oct 2029 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    Avastin (bevacizumab) • temozolomide • irinotecan • Omblastys (131I-omburtamab) • dexamethasone injection • ondansetron intravenous
    1m
    Engineering Functionality Optimized fully human B7-H3 CAR T Cells for Enhanced Solid Tumor Therapy. (PubMed, bioRxiv)
    In pancreatic cancer, neuroblastoma, and glioblastoma xenograft models, CAR T cells incorporating the lead human binder Y111 were well tolerated and demonstrated superior antitumor activity compared with 376.96- and MGA271-based CARs. Y111 CAR treatment induced complete responses, tumor rejection, and significant survival benefits, identifying Y111 as a promising fully human B7-H3 CAR for solid tumors.
    Journal
    |
    CD276 (CD276 Molecule)
    |
    enoblituzumab (MGA271)
    1m
    177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=61, Recruiting, Radiopharm Theranostics, Ltd | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Feb 2026
    Enrollment open • Trial initiation date
    1m
    Prognostic Impact of Treatment Modalities, Including Targeted Compartmental Radio-Immunotherapy, in a Cohort of Neuroblastoma Patients With CNS Metastases at Relapse. (PubMed, Pediatr Blood Cancer)
    In our experience, MYCN amplification and concomitant extra-CNS metastases at CNS relapse significantly decrease OS. Multimodal treatment, including 131I-omburtamab radioimmunotherapy, significantly improves survival outcomes.
    Journal
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    Omblastys (131I-omburtamab)
    1m
    The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334. (clinicaltrials.gov)
    P1/2, N=28, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Completed | N=128 --> 28 | Trial completion date: Jun 2026 --> Mar 2025 | Trial primary completion date: Oct 2025 --> Mar 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    IBI-334
    5ms
    177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=61, Not yet recruiting, Radiopharm Theranostics, Ltd
    New P1/2 trial
    6ms
    COBRA: First-in-Human Study of TAK-280 in Participants With Solid Tumors (clinicaltrials.gov)
    P1/2, N=69, Terminated, Takeda | Active, not recruiting --> Terminated; Terminated due to limited anti-cancer activity
    Trial termination
    6ms
    A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors. (PubMed, Cancer Res Commun)
    B7-H3 is expressed on a high proportion of pediatric solid tumors. While enoblituzumab could be safely administered at a weekly dose of 15 mg/kg, no objective tumor responses were observed. Alternative strategies to target B7-H3 in children with relapsed solid tumors should be considered.
    Journal
    |
    CD276 (CD276 Molecule)
    |
    enoblituzumab (MGA271)
    6ms
    XmAb808-01: Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=60, Completed, Xencor, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab)
    7ms
    Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jul 2025 --> Jul 2026
    Trial completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    enoblituzumab (MGA271)
    7ms
    A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Omblastys (131I-omburtamab)